Exelixis, Aurigene strike deal to discover and develop novel therapies for cancer

This article was originally published here

The agreement gives Exelixis the opportunity to in-license as many as six programs from Aurigene, which has developed a focused approach to drug discovery that targets differentiated first-in-class

The post Exelixis, Aurigene strike deal to discover and develop novel therapies for cancer appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply